One of the earliest products that may see a benefit from the paediatric SPC extension in Germany is Merck's Cozaar (losartan potassium). The German SPC is due to expire on September 2 2009, and Merck applied in due time for a paediatric extension with the German Patent Office on February 27 2009, filing an extensive compilation of supporting documents. In accordance with a Notice of the German Patent and Trade Mark Office dated January 28 2009, concerning the implementation and interpretation of the Paediatric Regulation Number 1901/2006, the request for paediatric extension included the results of all studies performed in compliance with the paediatric investigation plan agreed to by the EMEA and also a copy of an EU Commission decision that it has been verified that the application for the corresponding marketing authorisation includes these results.